Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult Schizophrenia Treatment
27/9 03:31
(RTTNews) - Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults....